Neuroprotective Agent LT3001 Heads to Phase 3 Study Following Positive Phase 2 Trials in Acute Ischemic Stroke

New data from 2 phase 2 trials showed that LT3001 (Lumosa), a first-in-class multifunctional compound, was safe for patients with disabling strokes, and led to clinically meaningful improvements at day 90. Despite the limitations of the studies, the investigators concluded that the findings support advancement into a global phase 3 trial, which is currently being planned.^1,2

Presented as a late-breaker at the 2026 International Stroke Conference (ISC), held February 5-7 in New Orleans, Louisiana, the data was from Study 202 and Study 205, two double-blind, placebo-controlled trials that spanned across China, the US, EU, and Taiwan. Across the two studies, 385 patients with acute ischemic stroke (AIS) were included, with baseline characteristics that were well balanced for the most part.

On the primary outcome of safety, LT3001 was shown to be a safe agent, with no increase in symptomatic intracranial hemorrhage (sICH) across both the 0.05 mg/kg and 0.025 mg/kg cohorts. Mortality was also similar between all groups, as there was only 1 death in Study 202 (in the LT3001 0.025 mg/kg group), and 5 deaths in Study 205 (LT3001 0.05 mg/kg: n = 4; placebo: n = 1).

Coming into the study, the median ages of patients in 202 and 205 were 64 and 68 years, respectively. Patients in Study 202 had shorter median treatment window of 12 hours, compared with 16 hours in 205. The median National Institutes of Health Stroke Scale (NIHSS) scores were both around 8 for each study, although the majority of patients in 202 had more moderately sized strokes relative to 205. Of note, study 202 captured TOAST classification, whereas 205 did not. Within 202, the most common etiology was LAA, accounting for 53%, 58%, and 60% of those in the LT3001 0.05 mg/kg, 0.025 mg/kg, and placebo groups, respectively.

“Across the two Phase 2 trials, LT3001 demonstrated a favorable safety profile, with no increase in symptomatic intracranial hemorrhage (sICH) despite multi-dose administration over 3 days,” principal investigator Thomas Devlin, MD, PhD, FSVIN, director of the CHI Memorial Neuroscience Institute, said in a statement.² “LT3001 showed potential benefit beyond the conventional thrombolytic time window, supporting its use in patients ineligible for IV thrombolysis or EVT, a population with high unmet need. The consistency of results across two independent trials, using different selection strategies, strengthens our confidence in LT3001's broad applicability.”

Study 202

In this trial, patients on higher dose LT3001 had an absolute improvement of 7% in modified Rankin Scale (mRS) scores between 0-2 overall over placebo. In the moderate stroke subgroup (NIHSS 7–10), which comprised more than 55% of patients, both doses were associated with a 9% improvement in achieving mRS 0–2. In the severe subgroup (NIHSS 11–25), the 0.05 dose demonstrated a 12% improvement in mRS 0–2, whereas patients with mild stroke (NIHSS 4–6) showed high placebo recovery rates and no observable treatment-related signal of improvement.

Conducted in China, study treatment effects varied by presenting neurologic deficit but generally favored active therapy over placebo at day 90. Among patients with arm motor drift, mRS 0–2 was achieved in 63% of both the 0.025 mg/kg and 0.05 mg/kg groups compared with 42% in the placebo arm, corresponding to absolute differences of 21% for each dose (RR 1.31 [95% CI, 0.82–2.09] and 1.36 [95% CI, 0.86–2.15], respectively). For leg motor drift, mRS 0–2 rates were 69% and 71% with the 0.025 mg/kg and 0.05 mg/kg doses versus 57% with placebo, reflecting 12% and 14% absolute differences.

Similar directional trends were observed in patients with motor drift affecting either arms or legs, where mRS 0–2 was achieved in 67% and 70% of treated patients compared with 55% of placebo-treated patients. In those presenting with language deficits or aphasia, mRS 0–2 rates were 76% and 78% in the active treatment groups versus 62% with placebo, representing absolute improvements of 13% and 16%, respectively. Across subgroups, the relative risks favored treatment, although confidence intervals crossed unity in most comparisons.

Study 205

When stratifying groups based on NIHSS, results showed no consistent positive signal in Study 205. Authors noted however that the number of patients included to power the study was low due to early stopping.

In the global 205 study, outcomes at day 90 showed variable effects of the 0.05 mg/kg dose compared with placebo across subgroups. Among those with arm motor drift (0.05 mg/kg: n = 10; placebo: n = 12), mRS 0–1 was achieved in 30% of treated patients versus 17% with placebo, an absolute difference of 13% (RR 1.80; 95% CI, 0.37–8.74), while mRS 0–2 occurred in 40% versus 42%, respectively (−2% difference; RR 0.96; 95% CI, 0.35–2.64).

In patients with leg motor drive, mRS 0–1 rates were 25% with treatment and 11% with placebo, a 14% difference (RR 2.35; 95% CI, 0.25–20.38), and mRS 0–2 was achieved in 25% versus 22% (3% difference; RR 1.13; 95% CI, 0.20–6.24).

Among those with arm or leg motor drift and those with language/aphasia issues, results were mixed. In the former, mRS 0–1 occurred in 27% on LT3001 versus 17% (11% difference; RR 1.64; 95% CI, 0.33–8.03) on placebo, while mRS 0–2 was 36% versus 42% (−5% difference; RR 0.87; 95% CI, 0.31–2.44). In the latter subgroup, mRS 0–1 was lower with treatment (21%) compared with placebo (56%), a −35% difference (RR 0.38; 95% CI, 0.13–1.14), and mRS 0–2 was 64% versus 75% (−11% difference; RR 0.86; 95% CI, 0.53–1.39). Across groups, confidence intervals were wide, reflecting small sample sizes and variability in effect estimates.

Phase 3 Target Population

Exploratory analyses indicated a potential directional benefit of LT3001 in a balanced, high-risk acute ischemic stroke subgroup characterized by moderate severity (NIHSS around 10) and late presentation (last known normal greater than 12 hours), which accounted for approximately 40% of Study 202 participants. In this cohort, treatment was associated with a numerical 11% to 14% improvement in day-90 functional outcomes, supporting further investigation in enriched patient populations.

“Despite over five decades of research and thousands of potential drug targets, the development of neuroprotective drugs for conditions like stroke has not resulted in any FDA-approved drugs in the U.S.,” Sheng-Wen Yeh, PhD, general manager at Lumosa, said in a statement. “While many drugs frequently succeed in preclinical, animal-based studies, they fail to show safety or efficacy in human trials. Our efficacy data with LT3001, spanning diverse patient populations, is exciting and provides direction for our Phase 3 programs.”

Click here for more ISC 2026 coverage.

REFERENCES
1. Devlin T, Yeh S. Lumosa LT3001 Improves Functional Outcomes in Disabling Acute Ischemic Stroke: Results from Two Phase 2 Clinical Trials. Presented at: ISC 2026; February 5-7; New Orleans, LA.
2. LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING ACUTE ISCHEMIC STROKE. Lumosa Therapeutics. February 7, 2026. Accessed February 18, 2026. https://www.prnewswire.com/apac/news-releases/lt3001-demonstrates-functional-improvements-in-patients-with-disabling-acute-ischemic-stroke-302681218.html